Showing 3591-3600 of 9661 results for "".
- VALOR Data Show Sustained Skin Improvement With Brepocitinibhttps://practicaldermatology.com/news/valor-data-show-sustained-skin-improvement-with-brepocitinib/2488826/Once-daily oral brepocitinib 30 mg demonstrated rapid and sustained improvements in cutaneous disease activity, pruritus, and skin-related quality of life among adults with dermatomyositis, according to a prespecified secondary analysis of the phase 3 VALOR trial published in JAMA Dermatology
- Lutikizumab Meets Primary Endpoint in Phase 3 Hidradenitis Suppurativa Trialhttps://practicaldermatology.com/news/lutikizumab-meets-primary-endpoint-in-phase-3-hidradenitis-suppurativa-trial/2488774/AbbVie announced positive topline results from the Phase 3 INTREPID trial evaluating lutikizumab, an investigational dual IL-1α/IL-1β antagonist, in adults and adolescents with moderate-to-severe hidradenitis suppurativa (HS). The randomized, double-blind, placebo-co
- Phase 3 Trial of Oral Minoxidil Formulation Meets Primary Endpoints in Male Pattern Hair Losshttps://practicaldermatology.com/news/phase-3-trial-of-oral-minoxidil-formulation-meets-primary-endpoints-in-male-pattern-hair-loss/2488751/Veradermics announced positive topline results from its Phase 3 Study 304 evaluating VDPHL01, an investigational extended-release oral minoxidil formulation, in men with mild-to-moderate androgenetic alopecia. The randomized, double-blind, placebo-controlled trial met both co-primary endpoints at
- "20 Tips in 20 Minutes" Offers Practical Pearls at Fall Clinicalhttps://practicaldermatology.com/news/20-tips-in-20-minutes-offers-practical-pearls-at-fall-clinical/2488740/Five dermatologists shared rapid-fire clinical, procedural, and practice-management advice, ranging from alopecia photography and nail examination to infantile hemangiomas, reimbursement, and patient communication at the 2026 Fall Clinical Dermatology Conference. The fast-moving "20 Tips i
- Fall Clinical Talk Highlights KIT Inhibition's Promise for Chronic Spontaneous Urticariahttps://practicaldermatology.com/news/fall-clinical-talk-highlights-kit-inhibitions-promise-for-chronic-spontaneous-urticaria/2488733/Emerging evidence supports KIT inhibition as a novel therapeutic approach, Naiem Issa, MD, PhD, FAAD, said in a talk at the 2026 Fall Clinical Dermatology Conference. Targeting the KIT signaling pathway may offer a new treatment strategy for patients with chronic spontaneous urticaria (CSU
- Dr. James Del Rosso Reviews Emerging Topical Therapieshttps://practicaldermatology.com/news/dr-james-del-rosso-reviews-emerging-topical-therapies/2488730/Advances in photoprotection, sebum-targeted acne treatment, and nonsteroidal topical therapies are expanding the range of topical options available to dermatologists, according to James Q. Del Rosso, DO, in one of his annual presentations at the 2026 Fall Clinical Dermatology Conference, titled "
- Bimekizumab-Treated Patients With Hidradenitis Suppurativa Remained Flare-Free Through 3 Years in Extension Studyhttps://practicaldermatology.com/news/bimekizumab-treated-patients-with-hidradenitis-suppurativa-remained-flare-free-through-3-years-in-extension-study/2488712/Most evaluable patients with moderate-to-severe hidradenitis suppurativa (HS) receiving bimekizumab remained free of observed flares through 148 weeks, according to pooled BE HEARD I and II and BE HEARD EXT data presented at the 2026 Fall Clinical Dermatology Conference. The analysis inclu
- ORKA-001 Shows Sustained Skin Clearance Through Week 28 in Phase 2a Psoriasis Trialhttps://practicaldermatology.com/news/orka-001-shows-sustained-skin-clearance-through-week-28-in-phase-2a-psoriasis-trial/2488711/The investigational IL-23p19 inhibitor ORKA-001 produced high rates of complete skin clearance through week 28 in adults with moderate-to-severe plaque psoriasis who received their last dose at week 4, according to results from the phase 2a EVERLAST-A trial presented in a research poster at the 2
- Study Links Lichen Planus to Increased Oral and Genital Cancer Riskhttps://practicaldermatology.com/news/study-links-lichen-planus-to-increased-oral-and-genital-cancer-risk/2488704/A nationwide Danish cohort study found that patients with lichen planus (LP) had an increased risk of oral, genital, and cutaneous cancers, with the strongest associations observed at anatomical sites affected by the inflammatory condition. The findings, published in JAMA Dermatology, sh
- Real-World RELIEVE-PN Data Show Sustained Itch and Skin Pain Improvements With Dupilumabhttps://practicaldermatology.com/news/real-world-relieve-pn-data-show-sustained-itch-and-skin-pain-improvements-with-dupilumab/2488708/Adults with prurigo nodularis (PN) who initiated dupilumab reported reductions in itch, skin pain, and burning or stinging/tingling symptoms as early as 1 month, with improvements maintained through 9 months, according to a real-world analysis presented at the 2026 Fall Clinical Dermatology Confe